A phase 2 dose-finding study of an extended-release tablet formulation of ketamine in patients with treatment-resistant depression shows that this formulation overcomes many of the limitations associated with the use of intravenous or intranasal ketamine formulations.
- Paul Glue
- Colleen Loo
- Yu-Jui Huang